NCT06097910 is a clinical trial of Watchful waiting in Lung Ground-glass Opacities, sponsored by Fudan University.

Who is sponsoring NCT06097910?

NCT06097910 is sponsored by Fudan University.

What drugs are being tested in NCT06097910?

Interventions in NCT06097910: Watchful waiting.

What condition does NCT06097910 study?

NCT06097910 studies Lung Ground-glass Opacities, Active Surveillance.

Is NCT06097910 still recruiting?

NCT06097910 is currently recruiting now. Last updated 31 January 2025.

Last reviewed 2025-01-31 · How we verify

NCT06097910

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surveillance for Multifocal GGNs

Recruiting now Last updated 31 January 2025

What this trial tests

trial testing Watchful waiting in Lung Ground-glass Opacities in 370 participants. Currently enrolling.

Timeline

1 November 2023

Primary endpoint
1 November 2036

1 November 2036

Quick facts

Lead sponsor	Fudan University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	370
Start date	1 November 2023
Primary completion	1 November 2036
Estimated completion	1 November 2036
Sites	1 location across China

Drugs / interventions tested

Watchful waiting

Conditions studied

Lung Ground-glass Opacities — all drugs for Lung Ground-glass Opacities →
Active Surveillance — all drugs for Active Surveillance →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Lung Ground-glass Opacities or Active Surveillance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, multi-center, phase III trial conducted under the Eastern Cooperative Thoracic Oncoloy Project (ECTOP) with the identification number ECTOP-1021. The primary objective of the study is to assess the overall survival of patients with multifocal ground-glass opacities by employing a active surveillance approach rather than opting for surgical resection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Active Surveillance of Multifocal Ground-Glass Opacities: Results of a Prospective Multicenter Trial (ECTOP1021).
Wu H, Fu F, Ye T, Hu H, et al · · 2026 · cited 2× · PMID 40983284 · DOI 10.1016/j.jtho.2025.09.011
Active surveillance for patients with multifocal ground-glass nodules: protocol of a prospective, multi-center, single-arm trial (ECTOP-1021).
Wu H, Deng P, Fu F, Zhang Y, et al · · 2025 · cited 2× · PMID 40400915 · DOI 10.21037/jtd-2024-1956
Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches.
Ohtaki Y, Aokage K, Miyoshi T, Tane K, et al · · 2026 · PMID 41642077 · DOI 10.1093/jjco/hyag013

Verify or expand the search:

Other trials of Watchful waiting

Trials testing the same drug.

NCT06391359 — Preventing Recurrent 'Idiopathic' Acute Pancreatitis Through Laparoscopic Cholecystectomy (PICUS-2) · NA · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06097910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 31 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06097910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing